Evidence map›Paper›PMID 31249914›Full record

ArticleTH open : companion journal to thrombosis and haemostasis2017

Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E-Deficient Mice.

A Sugidachi, K Ohno, J A Jakubowski, Y Ito, A Tomizawa, M Mizuno

Open access · goldAbstract read
In one paragraph

Article in TH open : companion journal to thrombosis and haemostasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

A SugidachiRare Disease and LCM Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
K OhnoRare Disease and LCM Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
J A JakubowskiLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States.
Y ItoRare Disease and LCM Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
A TomizawaRare Disease and LCM Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
M MizunoRare Disease and LCM Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Daiichi-Sankyo (Japan) · JPEli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with acute coronary syndrome with diabetes mellitus (DM) exhibit an impaired platelet inhibitory response to clopidogrel which is only partially understood. DM was induced by the administration of streptozotocin (STZ) to 9-week-old mice. The antithrombotic effects of clopidogrel (10 mg/kg/d, orally × 5 days) were determined using a FeCl

Indexed as

apolipoprotein E–deficient mouseclopidogreldiabetes mellitusP2Y 12plateletsthrombinthrombosis

Identifiers

PMID31249914
PMCPMC6524843
OpenAlexW2744059901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.